Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 15

1.

A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure.

Hawkins J, Kodali S, Matsuka YV, McNeil LK, Mininni T, Scully IL, Vernachio JH, Severina E, Girgenti D, Jansen KU, Anderson AS, Donald RG.

Clin Vaccine Immunol. 2012 Oct;19(10):1641-50. Epub 2012 Aug 15.

2.

[Prevention and immunotherapy of staphylococcal infections with bacterial vaccines].

Kuz'menko OM, Gruber IM, Priiatkin RG.

Zh Mikrobiol Epidemiol Immunobiol. 2010 Sep-Oct;(5):106-12. Review. Russian.

PMID:
21061586
3.

Vaccination and passive immunisation against Staphylococcus aureus.

Schaffer AC, Lee JC.

Int J Antimicrob Agents. 2008 Nov;32 Suppl 1:S71-8. doi: 10.1016/j.ijantimicag.2008.06.009. Epub 2008 Aug 30. Review.

PMID:
18757184
4.

Exploring Staphylococcus aureus pathways to disease for vaccine development.

DeDent A, Kim HK, Missiakas D, Schneewind O.

Semin Immunopathol. 2012 Mar;34(2):317-33. doi: 10.1007/s00281-011-0299-z. Epub 2011 Dec 1. Review.

6.

Development of a vaccine against Staphylococcus aureus.

Spellberg B, Daum R.

Semin Immunopathol. 2012 Mar;34(2):335-48. doi: 10.1007/s00281-011-0293-5. Epub 2011 Nov 14. Review.

7.

Vaccine review: "Staphyloccocus aureus vaccines: problems and prospects".

Jansen KU, Girgenti DQ, Scully IL, Anderson AS.

Vaccine. 2013 Jun 7;31(25):2723-30. doi: 10.1016/j.vaccine.2013.04.002. Epub 2013 Apr 23. Review.

PMID:
23624095
8.

Novel targeted immunotherapy approaches for staphylococcal infection.

Otto M.

Expert Opin Biol Ther. 2010 Jul;10(7):1049-59. doi: 10.1517/14712598.2010.495115. Review.

9.

Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors.

Anderson AS, Miller AA, Donald RG, Scully IL, Nanra JS, Cooper D, Jansen KU.

Hum Vaccin Immunother. 2012 Nov 1;8(11):1585-94. doi: 10.4161/hv.21872. Epub 2012 Aug 24. Review.

10.

Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials.

Bagnoli F, Bertholet S, Grandi G.

Front Cell Infect Microbiol. 2012 Feb 22;2:16. doi: 10.3389/fcimb.2012.00016. eCollection 2012. Review. No abstract available.

11.

The adhesive and immunomodulating properties of the multifunctional Staphylococcus aureus protein Eap.

Harraghy N, Hussain M, Haggar A, Chavakis T, Sinha B, Herrmann M, Flock JI.

Microbiology. 2003 Oct;149(Pt 10):2701-7. Review.

PMID:
14523103
12.

Staphylococcal vaccine development: review of past failures and plea for a future evaluation of vaccine efficacy not only on staphylococcal infections but also on mucosal carriage.

Botelho-Nevers E, Verhoeven P, Paul S, Grattard F, Pozzetto B, Berthelot P, Lucht F.

Expert Rev Vaccines. 2013 Nov;12(11):1249-59. doi: 10.1586/14760584.2013.840091. Epub 2013 Oct 10. Review.

PMID:
24111513
13.

Vaccine development in Staphylococcus aureus: taking the biofilm phenotype into consideration.

Harro JM, Peters BM, O'May GA, Archer N, Kerns P, Prabhakara R, Shirtliff ME.

FEMS Immunol Med Microbiol. 2010 Aug;59(3):306-23. doi: 10.1111/j.1574-695X.2010.00708.x. Epub 2010 May 29. Review.

14.

Where does a Staphylococcus aureus vaccine stand?

Fowler VG Jr, Proctor RA.

Clin Microbiol Infect. 2014 May;20 Suppl 5:66-75. doi: 10.1111/1469-0691.12570. Review.

15.

Covering all the Bases: Preclinical Development of an Effective Staphylococcus aureus Vaccine.

Scully IL, Liberator PA, Jansen KU, Anderson AS.

Front Immunol. 2014 Mar 24;5:109. doi: 10.3389/fimmu.2014.00109. eCollection 2014. Review.

Items per page

Supplemental Content

Write to the Help Desk